Skip to main content
. 2020 Feb 18;10:2815. doi: 10.1038/s41598-020-59736-3

Figure 5.

Figure 5

TF-CAR-NK cell therapy was effective and safe for the treatment of human TNBC PDX in an orthotopic NSG mouse model. TNBC PDX (JAX) was generated in four-week old female NSG mice, as described above and in our published study14. When the PDX tumors reached ~100 mm3, NK-CAR1 dimer (NK92MI/fCD16/CAR1 dimer) or NK92MI/fCD16 cells without CAR constructs (as a control) were injected i.v. via tail veins two times (3 × 106 cells per mouse on day 0 and 2 × 106 cells per mouse on day 17, arrows) (five mice per group). (A) Tumor volumes. (B,C) Tumor weights and mouse body weights were measured at the time of sacrifice of animals. ns: no significance; *, **, ***, ****p < 0.05, 0.01, 0.001 and 0.0001.